Another Drug Price Hike

Valeant Pharmaceuticals is criticized for jacking up the price of a drug used in assisted suicide.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, AYENAOut-of-control pharmaceutical price-hiking is in the news again. After a Congressional investigation into the practice of drugmaker Valeant Pharmaceuticals buying older heart medications and raising their prices exponentially, the firm is on the hot seat once again—this time for doubling the price of a decades-old sleeping pill that is now used in instances of assisted suicide. Doctors prescribe the pill, Seconal (secobarbital), in cases of physician-assisted suicide, which voters in California made legal starting this June. Valeant bought the rights to Seconal last February—a month after California legislators proposed legalizing physician-assisted suicide—and immediately raised its price from $1,500 to $,3000.

“It’s just pharmaceutical company greed,” David Grube, a family physician in Oregon, told KQED, the San Francisco-based public radio station that broke the story. “It’s not a complicated thing to make, there’s no research being done on it, there’s no development,” he added. “That to me is unconscionable.”

Valeant came under fire last year when the company inflated the prices of two heart medications by 200 percent and 500 percent. The House of Representatives is still investigating those cases of alleged price gouging, The New York Times reported.

“Valeant sets prices for drugs based on a number of factors,” the company told KQED in a statement. “When possible, we offer patient assistance programs to mitigate the effects of price adjustments and keep out-of-pocket costs affordable ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Image of a woman with her hands across her stomach. She has a look of discomfort on her face. There is a blown up image of her stomach next to her and it has colorful butterflies and gut bacteria all swarming within the gut.
November 2025, Issue 1

Why Do We Feel Butterflies in the Stomach?

These fluttering sensations are the brain’s reaction to certain emotions, which can be amplified or soothed by the gut’s own “bugs".

View this Issue
Olga Anczukow and Ryan Englander discuss how transcriptome splicing affects immune system function in lung cancer.

Long-Read RNA Sequencing Reveals a Regulatory Role for Splicing in Immunotherapy Responses

Pacific Biosciences logo
Research Roundtable: The Evolving World of Spatial Biology

Research Roundtable: The Evolving World of Spatial Biology

Conceptual cartoon image of gene editing technology

Exploring the State of the Art in Gene Editing Techniques

Bio-Rad
Conceptual image of a doctor holding a brain puzzle, representing Alzheimer's disease diagnosis.

Simplifying Early Alzheimer’s Disease Diagnosis with Blood Testing

fujirebio logo

Products

Labvantage Logo

LabVantage Solutions Awarded $22.3 Million U.S Customs and Border Protection Contract to Deliver Next-Generation Forensic LIMS

The Scientist Placeholder Image

Evosep Unveils Open Innovation Initiative to Expand Standardization in Proteomics

OGT logo

OGT expands MRD detection capabilities with new SureSeq Myeloid MRD Plus NGS Panel